Determination of 5-Fluorouracil in 5-Fluorouracil Injection and Human Serum by HPLC

高效液相層析法測定注射液及血清中5-Fluorouracil

祝玲(Ling Zhu) ； 申貴雋(Gui-Jun Shen) ； 丁仕強(Shi-Qiang Ding) ； 華欣(Xin Hua)

《藥物食品分析》 20卷4期 (2012/12) Pp. 947-950+986

https://doi.org/10.6227/jfda.2012200425

摘要

本研究開發一測定注射液及血清中5-Fluorouracil（5-FU）之高效液相層析法，層析管柱為Nova-park C18（3.9 × 150 mm, 4.6 μm），移動相為5 mmol/L磷酸二氫鉀（pH 6.0）：甲醇（96：4, v/v），流速為1.0 mL/min，檢測波長為254 nm，血清經AgNO3（20%）和NaCl（20%）前處理，濃度範圍0.1-100 μg/mL（R^2 = 0.9999）時呈良好線性。5-FU注射液及血清中5-FU之最低檢出限量分別為0.10和0.85 μg/mL（S/N = 10），不同濃度的平均回收率分別為95.79 - 105.1%和90.2 - 108.8%。精密度相對標差RSD為0.4%，注射液和血清的穩定性和再現性分別小於1.3和2.1%（n = 5）。血清中之不純物不會產生干擾，以本方法測定5-FU注射液及血清中5-FU具簡單、快速、敏感且精確等優點。

關鍵字

高效液相層析 ； 5-FU ； 血清 ； 濃度

並列摘要

A high-performance liquid chromatography (HPLC) method was developed for the determination of 5-fluorouracil (5-FU) in 5-FU injection and human serum. A Nova-park C18 column (3.9 × 150 mm, 4.6 μm) and mobile phase consisting of 5 mmol/L KH2PO4 (pH 6.0) - methanol (96:4, v/v) at a flow rate of 1.0 mL/min were used for separation. The detection wavelength was set at 254 nm. The human serum was treated with AgNO3 (20%) and NaCl (20%). The method showed a good linear relationship in the range of 0.1 - 100 μg/mL (R^2 = 0.9999) with limits of quantification (LOQ) at 0.10 μg/mL and 0.85 μg/mL (S/N = 10) in 5-FU injection and human serum, respectively. The average recoveries of different concentrations in 5-FU injection and human serum were 95.79 - 105.1% and 90.2 - 108.8%, respectively. The relative standard deviation (RSD) of precision was 0.4%, and those of stability and repeatability were less than 1.3% and 2.1% (n = 5) in both samples, respectively. Impurities in the human serum did not interfere with the determination of 5-FU. The method is simple, rapid, sensitive and can accurately determine 5-FU in 5-FU injection and human serum.

並列關鍵字

high performance liquid chromatography ； 5- FU ； human serum ； drug concentration

參考文獻

Longleg, D. B., Harkin, D. P. and Johnstor, P. G. 2003. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3: 330-338.

Malet-Martino, M. and Martino, R. L. 2002. Clinical studies of three oral prodrugs of 5-fluorouracil (Capecitabine, UFT, S-1): a review. Oncologist 7: 288-323.

Anderson, L. W., Parker, R. J. and Collins, J. M. et al. 1992. Gas chromatographic-mass spectrometric method for routine monitoring of 5-fluorouracil in plasma of patients receiving low-level protracted infusions. J. Chromatogr. 581: 195-201.

Shepard, D. R., Mani, S. and Kastrissios, H. et al.2002. Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil. Cancer Chemother. Pharmacol. 49: 398-402.

Buckpitt, A. R. and Boyd, M. R. 1980. A sensitive method for determination of 5-fluorouacil and 5-fluoro-2′-deoxyuridine in human plasma by high-pressure liquid chromatography. Anal. Biochem. 106: 432-437.